NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
Status:
Recruiting
Trial end date:
2021-02-15
Target enrollment:
Participant gender:
Summary
This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized
participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2
infection, in which participants will receive NA-831 or Atazanavir with or without
Dexamethasone.